BrightSpring Health Services, Inc. Common Stock
BTSG
$62.43
+3.02%
BrightSpring Health Services, Inc. is a home and community-based healthcare services platform that delivers complementary pharmacy and provider services to complex patients across Medicare, Medicaid, and commercially insured populations. The company operates through two primary segments: Pharmacy Solutions and Provider Services, with Pharmacy Solutions generating the majority of revenue. As a relatively new public entity (listed in January 2024), BrightSpring has quickly established itself as a key player in the healthcare services space, focusing on high-acuity, complex patient populations. The current investor narrative centers on the company's robust revenue growth, strategic divestitures (such as the sale of ResCare Community Living) to streamline operations, and its ability to capitalize on the secular shift toward home and community-based care, which has driven a remarkable stock performance over the past year.…
BTSG
BrightSpring Health Services, Inc. Common Stock
$62.43
Related headlines
Investment Opinion: Should I buy BTSG Today?
Based on the analysis, BTSG is rated a Buy. The company's robust revenue growth of 25.6% YoY, improving net margins from 1.0% to 4.1%, and strong analyst consensus with a 30.3% upside to the average target price support this rating. The forward PE of 26.6x is reasonable for a company with such growth, and the strategic divestiture of ResCare Community Living should enhance operational focus and profitability.
Sign up to view all
BTSG 12-Month Price Forecast
The AI assessment is bullish with medium confidence. BrightSpring's strong revenue growth and improving profitability are supported by favorable industry trends. However, the high debt and thin margins introduce uncertainty. The stance would be upgraded to high confidence if the company demonstrates sustained margin expansion and debt reduction. Conversely, a downgrade to neutral would occur if revenue growth decelerates below 15% or if margins deteriorate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on BrightSpring Health Services, Inc. Common Stock's 12-month outlook, with a consensus price target around $78.94 and implied upside of +26.4% versus the current price.
Average Target
$78.94
0 analysts
Implied Upside
+26.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $90
Analyst target range
The target price range spans from $70.00 to $90.00, with the high target implying a 48.5% upside, suggesting expectations of continued strong growth and potential multiple expansion. The low target of $70.00 still represents a 15.5% upside, indicating that even the most conservative analyst sees value. The relatively tight spread between low and high targets (28.6% of the average) suggests moderate uncertainty, but the overall bullish stance is clear. The recent ratings actions show no downgrades, only reaffirmations or upgrades, which reinforces the positive outlook. This strong analyst support, combined with the company's growth trajectory, positions BrightSpring as a favored pick in the healthcare services sector.
Bulls vs Bears: BTSG Investment Factors
BrightSpring presents a compelling growth story with accelerating revenue, improving profitability, and strong analyst support. However, the high valuation, significant debt, and thin margins introduce substantial risk. The bull case is currently stronger, driven by robust execution and secular tailwinds, but the stock's high beta and recent pullback highlight its vulnerability to market sentiment. The key tension is whether the company can sustain its growth trajectory and margin expansion to justify its premium valuation, or if rising costs and competition will compress margins and derail the narrative.
Bullish
- Revenue Growth Accelerating at 25.6% YoY: Q1 2026 revenue reached $3.61B, up 25.6% year-over-year, with sequential growth from $3.55B in Q4 2025 and $3.33B in Q3 2025. This consistent double-digit growth underscores strong demand for specialty pharmacy services and the company's ability to expand its market presence.
- Strong Analyst Consensus with 30% Upside: With 17 analysts, the average target price is $78.94, implying a 30.3% upside from the current price of $60.60. The low target of $70.00 still represents a 15.5% upside, and the recommendation is 'strong buy' with a mean score of 1.17, indicating broad bullish sentiment.
- Improving Profitability and Margin Expansion: Net income grew from $29.5M in Q1 2025 to $148.8M in Q1 2026, a fivefold increase, while net margin expanded from 1.0% to 4.1%. Operating margin also improved from 1.8% to 3.4%, reflecting operational leverage and successful cost management.
- Strategic Divestiture Sharpens Focus: The sale of ResCare Community Living to Sevita in March 2026 streamlines operations, allowing management to concentrate on higher-margin core businesses. This strategic move is expected to improve capital allocation and operational efficiency.
Bearish
- High Valuation with Trailing PE of 39.8x: The trailing PE of 39.8x is elevated, though the forward PE of 26.6x suggests expected earnings growth. However, the PEG ratio is negative (-0.04), indicating that near-term earnings growth expectations are negative, which is a red flag for valuation sustainability.
- High Debt Levels with Debt-to-Equity of 1.44: The debt-to-equity ratio of 1.44 indicates significant leverage, which increases financial risk. Interest expenses of $38.6M in Q1 2026 consume a substantial portion of operating income, limiting flexibility and making the company sensitive to interest rate changes.
- Thin Gross Margins at 11.8%: Gross margin is only 11.8%, reflecting the low-margin nature of pharmacy services. This leaves little room for error and makes profitability highly sensitive to cost increases or pricing pressures from payers.
- High Beta of 1.88 Amplifies Market Risk: With a beta of 1.88, the stock is nearly twice as volatile as the market. In a market downturn, BTSG could decline significantly more than the S&P 500, as evidenced by its -13.6% one-month return while the S&P gained 2.8%.
BTSG Technical Analysis
BrightSpring's stock has exhibited a powerful sustained uptrend over the past year, with a 1-year price change of +195.6%, dramatically outperforming the S&P 500's +21.5% gain. The current price of $60.60 sits at 82.2% of the 52-week range (between $20.075 low and $73.75 high), indicating the stock is trading near its highs but has pulled back from the peak. This positioning suggests strong momentum but also potential overextension, as the stock has more than tripled from its 52-week low, reflecting robust investor enthusiasm and a possible need for consolidation.
Beta
1.88
1.88x market volatility
Max Drawdown
-18.1%
Largest decline past year
52-Week Range
$21-$74
Price range past year
Annual Return
+205.1%
Cumulative gain past year
| Period | BTSG Return | S&P 500 |
|---|---|---|
| 1m | -11.4% | +2.4% |
| 3m | +13.9% | +4.6% |
| 6m | +57.3% | +11.7% |
| 1y | +205.1% | +21.4% |
| ytd | +62.6% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BTSG Fundamental Analysis
BrightSpring's revenue trajectory is robustly accelerating, with Q1 2026 revenue of $3.61 billion, up 25.6% year-over-year, and sequential growth from $3.55 billion in Q4 2025 and $3.33 billion in Q3 2025. The company's growth is driven by its Pharmacy Solutions segment, which benefits from increased demand for specialty pharmacy services, while the Provider Services segment is being streamlined through divestitures. This consistent double-digit growth underscores the company's ability to expand its market presence and capitalize on the growing complexity of patient care needs.
Quarterly Revenue
$3.6B
2026-03
Revenue YoY Growth
+25.6%
YoY Comparison
Gross Margin
13.3%
Latest Quarter
Free Cash Flow
$412118000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BTSG Overvalued?
Given that BrightSpring is profitable with a trailing net income of $148.8 million, the PE ratio is the primary valuation metric. The trailing PE stands at 39.8x, while the forward PE is 26.6x, implying the market expects significant earnings growth. The gap between trailing and forward PE suggests that analysts anticipate a substantial increase in EPS, which is consistent with the company's strong revenue growth and improving margins. This forward-looking optimism is also reflected in the PEG ratio of -0.04, though the negative value is due to the metric's calculation with negative earnings growth expectations in the near term, which is atypical and warrants caution.
PE
39.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~56x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
22.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financially, BrightSpring carries a debt-to-equity ratio of 1.44, indicating substantial leverage that increases interest expense and financial risk. With interest expenses of $38.6M in Q1 2026, the company's operating income of $121.4M is significantly burdened, leaving a thin margin of safety. The gross margin of 11.8% is extremely thin, making the business highly sensitive to cost inflation or pricing pressure from payers. Additionally, the negative PEG ratio of -0.04 suggests that near-term earnings growth expectations are negative, which could lead to earnings disappointments and multiple compression.
FAQ
The key risks include: 1) Financial risk from high debt (debt-to-equity of 1.44) and interest expenses, which could strain cash flow if rates rise. 2) Operational risk from thin gross margins (11.8%), making the business vulnerable to cost inflation. 3) Market risk from high beta (1.88), leading to amplified losses in market downturns. 4) Regulatory risk, as changes in Medicare/Medicaid reimbursement could impact revenue. The most severe risk is a combination of margin compression and rising rates, which could lead to a significant de-rating.
The 12-month forecast is bullish, with a base case target of $70-78 (50% probability), a bull case target of $78-90 (30% probability), and a bear case target of $50-60 (20% probability). The most likely scenario is the base case, where the stock reaches the analyst average target of $78.94, driven by continued revenue growth and margin expansion. The key assumption is that the company maintains its growth trajectory without major disruptions.
BTSG is trading at a forward PE of 26.6x, which is reasonable for a company with 25.6% revenue growth. The trailing PE of 39.8x is higher, reflecting the market's expectation of future earnings growth. Compared to the healthcare sector average, the valuation is at a premium, but this is justified by the company's superior growth. The negative PEG ratio is a concern, but it is due to near-term earnings volatility. Overall, the stock is fairly valued relative to its growth prospects, though not a bargain.
BTSG is a good buy for investors with a higher risk tolerance, given its strong growth prospects and analyst support. The average analyst target of $78.94 implies a 30.3% upside, and the stock has outperformed the market significantly over the past year. However, the high beta of 1.88 and recent pullback indicate volatility, so investors should be prepared for short-term fluctuations. The main risk is valuation compression if growth decelerates, but for those with a long-term horizon, the current valuation is justified by the growth trajectory.
BTSG is more suitable for long-term investment, given its growth stage and volatility. The company is in a high-growth phase with revenue accelerating, but the high beta (1.88) and recent price swings make it risky for short-term trading. Investors should have a minimum holding period of 3-5 years to ride out volatility and benefit from the secular growth in home-based care. The company does not pay a dividend, so returns will come from capital appreciation.